PAS
HRTX icon

PKS Advisory Services’s Heron Therapeutics HRTX Stock Holding History

PKS Advisory Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Buy
+20,000
New +$23.2K ﹤0.01% 228
2025
Q4 		– Sell
-20,000
Closed -$25.2K – 261
2025
Q3 		$25.2K Buy
+20,000
New +$31.7K 0.01% 244

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

PKS Advisory Services's HRTX Position: Q1 2026 in Review

PKS Advisory Services opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 20,000 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #228 among its holdings. This is a return to the name: PKS Advisory Services previously reported a position in HRTX as recently as Q3 2025.

PKS Advisory Services first reported a position in HRTX in Q3 2025 and has held it in 2 quarters since. The position peaked at $25.2K in Q3 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • PKS Advisory Services held 20,000 shares of Heron Therapeutics worth $16K as of Q1 2026.
  • Heron Therapeutics was a new PKS Advisory Services position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of PKS Advisory Services's portfolio in Q1 2026, its #228 holding.
  • PKS Advisory Services first reported a position in Heron Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • PKS Advisory Services's Heron Therapeutics position peaked at $25.2K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on PKS Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.